Hypera stock

HYPE3 · B3 · BRL

Compare Hypera
R$21.77Change from previous close: 0.00%

Close · November 22, 2026

Price history

−13.99% over the period

1 year: from R$25.31 (November 24, 2025) to R$21.77 (November 22, 2026), −13.99%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 22, 2026R$21.77
October 30, 2026R$21.27
September 30, 2026R$24.48
August 31, 2026R$21.70
July 31, 2026R$21.27
June 30, 2026R$20.81
May 29, 2026R$21.91
April 30, 2026R$22.53
March 31, 2026R$23.28
February 27, 2026R$23.08
January 30, 2026R$25.21
December 30, 2025R$23.56
November 28, 2025R$26.80
November 24, 2025R$25.31

At a glance

  • The company

    Pharmaceutical company offering sweeteners, analgesics, cold and flu remedies, antihistamines, antiseptics, herbal medicines, gastrointestinal products, generics, skincare, supplements and vitamins in Brazil

  • Latest results

    Quarter to September 30, 2026 · EPS R$0.75 (estimate R$0.69)

TickerLandia's take on Hypera

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowR$19.41
52-wk highR$30.00

−27.43% from the 52-week high

Analysts · 15 analysts

Average targetR$29.40+35.05% vs. price

Buy 14 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Hypera

Compared with similar companies: very low price.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 317 Latin American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Hypera is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Hypera's P/E today is 11.6, below the median of its last 10 fiscal years (16.7; between 8.59 and 25.9 from 2016 to 2025). Hypera's P/E (trailing 12 months): 8.09, −52% against the median of a group of 10 similar companies (17.0).

P/E compared with its history

Compared with 10 similar companies

Hypera's metrics compared with similar companies
MetricHyperaPosition in the groupBand
P/E (trailing 12 months)8.09Low
Forward P/E7.29Low
Operating margin28.1%High
ROE13.4%Middle
Debt/equity0.53Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Hypera. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

R$2.44B

Latest quarter · Q3 2026

Net income

R$523.15M

Latest quarter · Q3 2026

Quarterly net margin

21.5%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
R$15.33B
P/E
8.1
EPS
R$2.69
Volume
3.37M
Daily trading
€14.87M
Dividend yield
4.97%
Last ex-dividend on September 29, 2026

How Hypera is changing

All results
  • Revenue grew 13.5% a year on average over the last 5 years

  • Operating margin fell from 32.3% to 22.7%

  • Profits turn into cash: free cash flow equal to 145% of net income

Returns

Hypera returns with dividends

R$1,000 invested in Hypera 5 years ago, on November 22, 2021, would be worth R$929 today with dividends reinvested: −7.09% in total, −1.46% per year. On price alone it would be R$758 (−24.17%).

PeriodHyperaIbovespaR$1,000 becomes
1 month−17.79%−18.87%R$822
6 months−3.50%−5.58%R$965
Year to date−7.60%+3.26%R$924
1 year−9.83%+7.15%R$902
3 years−27.12%+32.01%R$729
5 years−7.09%+62.92%R$929
10 years+22.08%+168.55%R$1,221

Over the last 6 months it has done better than 25% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Ibovespa: with dividends. Calculate your investment

The chart in detail

Hypera: technical analysis

Hypera shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 57.2% below its all-time closing high (R$50.81, October 31, 2022).

Trend
No clear trend
RSI (14 sessions)
41
Between 30 and 70
vs 200-session average
−3.48%

Support and resistance

Price areas where Hypera has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. ResistanceR$23.74+9.03%4 touches, last on September 29, 2026
  2. ResistanceR$22.69+4.21%4 touches, last on August 7, 2026
  3. ResistanceR$21.93+0.72%9 touches, last on September 14, 2026
  4. Last priceR$21.77
  5. SupportR$20.50−5.85%3 touches, last on November 3, 2026
  6. SupportR$19.94−8.42%3 touches, last on July 24, 2026

Volatility and risk

Over the last year it has moved more than the Ibovespa.

Beta (1 year) vs Ibovespa
1.32
Volatility (60 sessions, annualised)
66.4%
Largest fall in the last year
−27.09%

In session, November 22, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Hypera: seasonality

Average monthly price change over 19 years

+1.4%Jan+0.7%Feb+3.7%Mar+2.2%Apr+3.3%May−0.9%Jun+1.5%Jul−1.1%Aug−0.6%Sep+0.8%Oct+0.7%Nov+0.1%Dec

Over the last 19 years, the strongest month for Hypera has been March: +3.71% on average, positive in 13 years out of 18. The weakest has been August: −1.10% on average, positive in 9 years out of 19. November, the current month, has been positive in 8 years out of 18 (+0.71% on average).

Show chart data
MonthAverageMedianPositive years
January+1.41%+2.80%12 of 18
February+0.65%+0.44%9 of 18
March+3.71%+2.44%13 of 18
April+2.19%+1.26%11 of 18
May+3.29%+5.02%12 of 19
June−0.90%−1.01%8 of 19
July+1.48%+0.63%12 of 19
August−1.10%−0.22%9 of 19
September−0.62%+2.74%10 of 19
October+0.79%+3.98%11 of 19
November+0.71%−2.90%8 of 18
December+0.11%+2.98%11 of 18

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Hypera and its competitors

Doril, Buscopan, Neosaldina and Engov are among the brands most people associate with Hypera S.A., a Brazilian drugmaker whose catalogue covers painkillers and anti-inflammatories, cold and flu remedies, antihistamines, digestive products, antiseptics such as Merthiolate, herbal medicines, vitamins, supplements and skincare lines. Its activities are concentrated in Brazil, and the group also sells generics under the neo quimica name as well as sweeteners under Adocyl and Zero-cal, with the Dramin and Cepacol brands rounding out its range.

Headquarters
São Paulo, Brazil
Employees
10,564
Founded
1999
Chief executive
Breno Pires de Oliveira
Hypera and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
HyperaHYPE3$2.58B28.1%8.09−3.50%
Genomma Lab InternacionalLAB/B$776.89M20.0%8.71−9.05%
AlmirallALM$2.45B9.6%30.2−9.84%
Siegfried HoldingSFZN$3.4B16.7%16.7−19.46%
Hims & Hers HealthHIMS$3.42B-6.4%—−36.63%
FagronFAGR$1.97B14.3%19.5−0.20%

Same industry or related industries, similar size. Compare Hypera with its competitors · Full profile